Clinical trial · Interventional
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia
NCT06470841CI-TRIAL-00080097not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CHG Combined With Venetoclax and Azacytidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CHG Combined With Venetoclax and Azacytidine
- description
- Patients were treated by CHG Combined With Venetoclax and Azacytidine
- interventionNames
- Drug: CHG Combined With Venetoclax and Azacytidine
Primary outcomes (1)
- measure
- Overall Response Rate (ORR)
- timeFrame
- 1 year
- description
- ORR was defined as the proportion of patients who achieved CR or PR as their best response
Secondary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- through study completion, an average of 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient should, in the investigator's opinion, be able to meet all clinical trial requirements. * The patient is willing and able to adhere to the study visit schedule and other protocol requirements. * The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO). * The patient should not have received any prior treatment for AML. Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. * Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.